+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antiviral Drugs Market by Mechanism of Action, Target Indication, Type of Drug Target, Type of Therapy and Key Geographies: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 194 Pages
  • September 2022
  • Region: Global
  • Roots Analysis
  • ID: 5691609
Description Jump to:

Infectious diseases are known to be one of the top 10 leading causes of deaths, worldwide. In-fact, more than 40 million people are affected by various types of infectious diseases annually. An article published in The Lancet journal reported that COVID-19 alone caused death of over 18 million people in 2020. Further, it has been reported that human immunodeficiency virus (HIV) is anticipated to be the cause for 6.5 million deaths globally, by 2030. Over the past few years, a number of antiviral drugs targeting a myriad of infectious diseases, including human immunodeficiency virus (HIV) infection, hepatitis, herpes simplex virus (HSV) infection, cytomegalovirus (CMV) infection, influenza, coronavirus infection (COVID-19) and others, have received approvals from various regulatory authorities, globally. However, it is important to note that, currently, the approved antiviral drugs (around 80) are capable of targeting only 10 of the 220 known viruses that are responsible for causing multiple life threatening infectious diseases in humans. Further, several antiviral drugs are being evaluated across multiple clinical trials for the treatment of various infectious diseases. Moreover, post the onset of the COVID-19 pandemic, extensive research is being conducted to evaluate the safety and efficacy of novel antiviral therapeutics.

The antiviral therapeutic development is fraught with several challenges, including emergence of drug resistance in viruses (as viruses can frequently mutate their genome) and concerns related to drug safety and efficacy. In order to address the aforementioned concerns, several industry stakeholders have been actively leading the R&D efforts for the development of effective antiviral therapeutics against the known viral targets. The COVID-19 pandemic also exposed the lack of effective antiviral therapeutics that can be used for the treatment of re-emerging or emerging viral diseases; this has created opportunities for the development of novel antiviral drugs that can be effective against multiple viruses. Presently, more than 375 companies are engaged in the development of over 420 early and late-stage antiviral drugs, worldwide. These stakeholders have established multiple partnerships and collaborations in order to advance the development of various pipeline candidates. Moreover, in order to fund product development initiatives in this domain, various private and public sector investors have invested around USD 5.5 billion across multiple instances. Driven by the increasing demand for safe and effective antivirals, ongoing pace of innovation in this field, recent partnership activity and sufficient financial support from investors, the antiviral drugs market is anticipated to witness substantial growth in the mid to long-term.

Scope of the Report

The ‘Antiviral Drugs Market, 2022-2035: Distribution by Mechanism of Action (Fusion Inhibitors, DNA Polymerases, Protease Inhibitors, Reverse Transcriptase Inhibitors and Others), Target Indication (Human Immunodeficiency virus Infection, Hepatitis, Herpes Simplex Virus Infection, Cytomegalovirus Infection, Influenza, Coronavirus Infection and Others), Type of Drug Target (Virus Targets and Host Targets), Type of Therapy (Monotherapy and Combination Therapy) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future potential of the antiviral drugs market. The study also includes an in-depth analysis, highlighting the capabilities of antiviral drug developers engaged in this domain. Amongst other elements, the report features:

  • A general overview of the antiviral drugs, along with information on types of viruses and viral diseases, different mechanism of action of antiviral drugs and characteristics and advantages offered by the antiviral drugs. The chapter concludes with a discussion on the challenges associated with the development of antiviral drugs and future prospects in this domain.
  • A detailed assessment of the current market landscape of commercially available antiviral drugs, based on several relevant parameters, such as year of approval, type of dosage form (tablets, capsules, liquids, powders and others /unspecified), type of molecule (small molecules, biologics), type of target virus (DNA virus and RNA virus), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), dosing frequency, mechanism of action (polymerase inhibition, protease inhibition, reverse transcriptase inhibition, nonnucleoside reverse transcriptase inhibition, integrase strand transfer inhibition, nucleoside reverse transcriptase inhibition, NS5A inhibition, CYP3A inhibition, neuraminidase inhibition, glycoprotein inhibition, immunostimulation, interferon alpha stimulation and viral fusion protein inhibition) and target indication (human immunodeficiency virus infection, hepatitis C infection, hepatitis B infection, herpes simplex virus infection, influenza virus infection, cytomegalovirus infection, coronavirus infection, ebolavirus infection and other indications). In addition, it provides details on the antiviral drug developers, along with analyses based on their year of establishment, company size, geographical location and leading players (in terms of number of approved antiviral drugs). 
  • A detailed assessment of the current market landscape of clinical-stage antiviral drugs, based on several relevant parameters, such as phase of development (phase I, phase I/II, phase II, phase II/III and phase III), type of molecule (small molecules, biologics), type of dosage form (tablets, capsules, liquids, powders and others /unspecified), route of administration (oral, intravenous, subcutaneous, intramuscular and others / unspecified), target indication (coronavirus infection, human immunodeficiency virus infection, hepatitis B infection, influenza virus infection, hepatitis C infection, respiratory syncytial virus infection, human papillomavirus infection, herpes simplex virus infection and other indications), type of developer (industry and industry / non-industry), type of therapy (monotherapy and combination therapy), target patient segment, mechanism of action (viral replication inhibition, anti-inflammation, immunostimulants, viral spike protein inhibition, interleukin receptor antagonists, polymerase inhibition, protease inhibition, viral entry inhibition, nucleoside reverse transcriptase inhibition, fusion protein inhibition, capsid protein inhibition, toll-like receptor antagonists, nonnucleoside reverse transcriptase inhibition, tyrosine kinase inhibition, viral core protein inhibition, Janus Kinases inhibition and HIV integrase inhibition), type of target virus (DNA virus and RNA virus) and number of doses. In addition, it provides details on the companies engaged in the development of clinical-stage antiviral drugs, based on their year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).
  • An analysis of partnerships that have been inked by stakeholders engaged in this domain, since 2019, covering instances of clinical trial agreements, R&D agreements, product development and commercialization agreements, manufacturing agreements, product development agreements, commercialization agreements, acquisitions and mergers, product licensing agreements, supply agreements, manufacturing and commercialization agreements, product development and distribution agreements, technology licensing agreements, manufacturing and distribution agreements, distribution agreements and others. Further, the partnership activity in this domain has been analyzed based on several relevant parameters, such as year of partnership, type of partnership, target indication, type of target virus, type of partner, most active players (in terms of number of partnerships) and regional distribution of collaborations. 
  • A detailed analysis of investments that have been made into companies engaged in the antiviral drugs domain, since 2019, capturing instances of venture capital financing, capital raised from IPOs and subsequent public offerings, grants, debts and other equity. 
  • A qualitative analysis of the five competitive forces, including threats for new entrants, bargaining power of drug developers, bargaining power of buyers, threats of substitute products and rivalry among existing competitors under an insightful Porter’s Five Forces framework.
  • Elaborate profiles of prominent players engaged in development of antiviral drugs, featuring a brief overview of the company, details on its product portfolio and recent developments with an informed future outlook. 

One of the key objectives of the report was to evaluate the current market size and the future potential associated with the antiviral drugs market, over the coming decades. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as mechanism of action (fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors and others), target indication (human immunodeficiency virus infection, hepatitis, herpes simplex virus infection, cytomegalovirus infection, influenza, coronavirus infection and others), type of drug target (virus targets and host targets), type of therapy (monotherapy and combination therapy) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the market’s evolution.

Key Questions Answered

  • Who are the key players that have marketed their proprietary antiviral drugs?
  • Who are the leading players currently engaged in the development of clinical-stage antiviral drugs?
  • Which popular disease indications are being targeted by antiviral drugs?
  • What type of partnership models are commonly adopted by industry stakeholders?
  • Who are the key investors supporting research and development related to antiviral drugs? 
  • What are the key value drivers that are likely to influence the evolution of the antiviral drugs market?
  • How is the current and future market opportunity, related to antiviral drugs likely to be distributed across key market segments?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Antiviral Drugs
3.2. Types of Viruses and Viral Diseases
3.3. Mechanism of Action of Antiviral Drugs
3.4. Characteristics of Antiviral Drugs
3.5. Advantages of Antiviral Drugs
3.6. Challenges Associated with Development of Antiviral Drugs
3.7. Key Facts and Future Perspectives of Antiviral Drugs

4. MARKET LANDSCAPE: APPROVED ANTIVIRAL DRUGS
4.1. Approved Antiviral Drugs: Overall Market Landscape
4.1.1. Analysis by Year of Approval
4.1.2. Analysis by Type of Dosage Form
4.1.3. Analysis by Type of Molecule
4.1.4. Analysis by Type of Target Virus
4.1.5. Analysis by Route of Administration
4.1.6. Analysis by Dosing Frequency
4.1.7. Analysis by Mechanism of Action
4.1.8. Analysis by Target Indication
4.2. Approved Antiviral Drugs: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography (Region-wise)
4.2.4. Analysis by Geography (Country-wise)
4.2.5. Most Active Players: Analysis by Number of Approved Drugs

5. MARKET LANDSCAPE: CLINICAL ANTIVIRAL DRUGS
5.1. Clinical-Stage Antiviral Drugs: Overall Market Landscape
5.1.1. Analysis by Phase of Development
5.1.2. Analysis by Type of Molecule
5.1.3. Analysis by Phase of Development and Type of Molecule
5.1.4. Analysis by Type of Dosage Form
5.1.5. Analysis by Route of Administration
5.1.6. Analysis by Target Indication
5.1.7. Analysis by Phase of Development and Target Indication
5.1.8. Analysis by Type of Developer
5.1.9. Analysis by Type of Therapy
5.1.10. Analysis by Target Patient Segment (by Age)
5.1.11. Analysis by Mechanism of Action
5.1.12. Analysis by Type of Target Virus
5.1.13. Analysis by Number of Doses
5.2. Clinical-Stage Antiviral Drugs: Developer Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Geography (Region-wise)
5.2.4. Analysis by Geography (Country-wise)
5.2.5. Analysis by Company Size and Location of Headquarters
5.2.6. Most Active Players: Analysis by Number of Clinical-Stage Drugs

6. COMPANY PROFILES
6.1. AbbVie
6.1.1. Company Overview
6.1.2. Key Executives
6.1.3. Financial Information
6.1.4. Product Portfolio
6.1.5. Recent Developments and Future Outlook
6.2. AstraZeneca
6.2.1. Company Overview
6.2.2. Key Executives
6.2.3. Financial Information
6.2.4. Product Portfolio
6.2.5. Recent Developments and Future Outlook
6.3. Bristol-Myers Squibb
6.3.1. Company Overview
6.3.2. Key Executives
6.3.3. Financial Information
6.3.4. Product Portfolio
6.3.5. Recent Developments and Future Outlook
6.4. Genentech
6.4.1. Company Overview
6.4.2. Key Executives
6.4.3. Product Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Gilead Sciences
6.5.1. Company Overview
6.5.2. Key Executives
6.5.3. Financial Information
6.5.4. Product Portfolio
6.5.5. Recent Developments and Future Outlook
6.6. GlaxoSmithKline (GSK)
6.6.1. Company Overview
6.6.2. Key Executives
6.6.3. Financial Information
6.6.4. Product Portfolio
6.6.5. Recent Developments and Future Outlook
6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Key Executives
6.7.3. Financial Information
6.7.4. Product Portfolio
6.7.5. Recent Developments and Future Outlook
6.8. Merck
6.8.1. Company Overview
6.8.2. Key Executives
6.8.3. Financial Information
6.8.4. Product Portfolio
6.8.5. Recent Developments and Future Outlook
6.9. Novartis
6.9.1. Company Overview
6.9.2. Key Executives
6.9.3. Financial Information
6.9.4. Product Portfolio
6.9.5. Recent Developments and Future Outlook
6.10. Pfizer
6.10.1. Company Overview
6.10.2. Key Executives
6.10.3. Financial Information
6.10.4. Product Portfolio
6.10.5. Recent Developments and Future Outlook
6.11. Roche
6.11.1. Company Overview
6.11.2. Key Executives
6.11.3. Financial Information
6.11.4. Product Portfolio
6.11.5. Recent Developments and Future Outlook
6.12. ViiV Healthcare
6.12.1. Company Overview
6.12.2. Key Executives
6.12.3. Product Portfolio
6.12.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Antiviral Drugs: Partnerships and Collaborations
7.1.1. Analysis by Year of Partnership
7.1.2. Analysis by Type of Partnership
7.1.3. Analysis by Year and Type of Partnership
7.1.4. Analysis by Target Indication
7.1.5. Analysis by Type of Target Virus
7.1.6. Analysis by Type of Partner
7.1.7. Most Active Players: Analysis by Number of Partnerships
7.1.8. Geographical Analysis
7.1.8.1. Intercontinental and Intracontinental Deals
7.1.8.2. International and Local Deals

8. FUNDING AND INVESTMENTS
8.1. Antiviral Drugs: Funding and Investments
8.1.1. Analysis by Year of Funding
8.1.2. Analysis of Amount Invested by Year
8.1.3 Analysis by Type of Funding
8.1.4. Analysis of Amount Invested by Type of Funding
8.1.5. Analysis by Target Indication
8.1.6. Analysis by Type of Target Virus
8.1.7. Analysis by Type of Investor
8.1.8. Most Active Players: Analysis by Number of Instances
8.1.9. Most Active Players: Analysis by Amount Invested
8.1.10. Most Active Investors: Analysis by Number of Instances
8.1.11. Geographical Analysis
8.1.11.1. Analysis of Amount Invested by Region
8.1.11.2. Analysis of Amount Invested by Country

9. PORTER’S FIVE FORCES ANALYSIS
9.1. Chapter Overview
9.2. Methodology and Key Parameters
9.3. Porter’s Five Forces
9.3.1. Threat of New Entrants
9.3.2. Bargaining Power of End Users
9.3.3. Bargaining Power of Drug Developers
9.3.4. Threat of Substitute Products
9.3.5. Rivalry Among Existing Competitors

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Forecast Methodology and Key Assumptions
10.2. Global Antiviral Drugs Market, 2022-2035
10.2.1. Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035
10.2.1.1. Antiviral Drugs Market for Fusion Inhibitors, 2022-2035
10.2.1.2. Antiviral Drugs Market for DNA Polymerases, 2022-2035
10.2.1.3. Antiviral Drugs Market for Protease Inhibitors, 2022-2035
10.2.1.4. Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035
10.2.1.5. Antiviral Drugs Market for Other Mechanisms, 2022-2035
10.2.2. Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035
10.2.2.1. Antiviral Drugs Market for Human Immunodeficiency virus Infection, 2022-2035
10.2.2.2. Antiviral Drugs Market for Hepatitis Infection, 2022-2035
10.2.2.3. Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035
10.2.2.4. Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035
10.2.2.5. Antiviral Drugs Market for Influenza Infection, 2022-2035
10.2.2.6. Antiviral Drugs Market for Coronaviruses Infection, 2022-2035
10.2.2.7. Antiviral Drugs Market for Other Target Indications, 2022-2035
10.2.3. Antiviral Drugs Market: Distribution by Type of Drug Target, 2022 and 2035
10.2.3.1. Antiviral Drugs Market for Virus Targets, 2022-2035
10.2.3.2. Antiviral Drugs Market for Host Targets, 2022-2035
10.2.4. Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035
10.2.4.1. Antiviral Drugs Market for Monotherapy, 2022-2035
10.2.4.2. Antiviral Drugs Market for Combination Therapy, 2022-2035
10.2.5. Antiviral Drugs Market: Distribution by Geography, 2022 and 2035
10.2.5.1. Antiviral Drugs Market in North America, 2022-2035
10.2.5.2. Antiviral Drugs Market in Europe, 2022-2035
10.2.5.3. Antiviral Drugs Market in Asia-Pacific, 2022-2035
10.2.5.4. Antiviral Drugs Market in Latin America, 2022-2035
10.2.5.5. Antiviral Drugs Market in MENA, 2022-2035
10.2.5.6. Antiviral Drugs Market in Rest of the World, 2022-2035

11. APPENDIX 1: TABULATED DATA12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Overall Market Landscape of Approved Antiviral Drugs
Figure 2.2 Executive Summary: Overall Market Landscape of Clinical Antiviral Drugs
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investments
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Viruses
Figure 3.2 Mechanism of Action of Antiviral Drugs
Figure 4.1 Approved Antiviral Drugs: Distribution by Year of Approval
Figure 4.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Figure 4.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Figure 4.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Figure 4.5 Approved Antiviral Drugs: Distribution by Route of Administration
Figure 4.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Figure 4.7 Approved Antiviral Drugs: Distribution by Mechanism of Action
Figure 4.8 Approved Antiviral Drugs: Distribution by Target Indication
Figure 4.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 4.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Figure 4.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 4.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 4.13 Most Active Players: Distribution by Number of Approved Drugs
Figure 5.1 Clinical Antiviral Drugs: Distribution by Phase of Development
Figure 5.2 Clinical Antiviral Drugs: Distribution by Type of Molecule
Figure 5.3 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Figure 5.4 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Figure 5.5 Clinical Antiviral Drugs: Distribution by Route of Administration
Figure 5.6 Clinical Antiviral Drugs: Distribution by Target Indication
Figure 5.7 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Figure 5.8 Clinical Antiviral Drugs: Distribution by Type of Developer
Figure 5.9 Clinical Antiviral Drugs: Distribution by Type of Therapy
Figure 5.10 Clinical Antiviral Drugs: Distribution by Target Patient Segment (by Age)
Figure 5.11 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Figure 5.12 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Figure 5.13 Clinical Antiviral Drugs: Distribution by Number of Doses
Figure 5.14 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Figure 5.15 Clinical Antiviral Drugs Developers: Distribution by Company Size
Figure 5.16 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Figure 5.17 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Figure 5.18 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Figure 5.19 Most Active Players: Distribution by Number of Clinical-Stage Drugs
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Target Indication
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Target Virus
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 7.7 Most Active Players: Distribution by Number of Partnerships
Figure 7.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 7.9 Partnerships and Collaborations: International and Local Deals
Figure 8.1 Funding and Investments: Distribution by Year of Funding
Figure 8.2 Funding and Investments: Distribution of Amount Invested by Year
Figure 8.3 Funding and Investments: Distribution by Type of Funding
Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding
Figure 8.5 Funding and Investments: Distribution by Target Indication
Figure 8.6 Funding and Investments: Distribution by Type of Target Virus
Figure 8.7 Funding and Investments: Distribution by Type of Investor
Figure 8.8 Most Active Players: Distribution by Number of Instances
Figure 8.9 Most Active Players: Distribution by Amount Invested
Figure 8.10 Most Active Investors: Distribution by Number of Instances
Figure 8.11 Funding and Investments: Distribution of Amount Invested by Region
Figure 8.12 Funding and Investments: Distribution of Amount Invested by Country
Figure 9.1 Antiviral Drugs: Porter’s Five Forces Analysis
Figure 10.1 Global Antiviral Drugs Market, 2022-2035 (USD Billion)
Figure 10.2 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Figure 10.3 Antiviral Drugs Market for Fusion Inhibitors, 2022-2035 (USD Billion)
Figure 10.4 Antiviral Drugs Market for DNA Polymerases, 2022-2035 (USD Billion)
Figure 10.5 Antiviral Drugs Market for Protease Inhibitors, 2022-2035 (USD Billion)
Figure 10.6 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, 2022-2035 (USD Billion)
Figure 10.7 Antiviral Drugs Market for Other Mechanisms, 2022-2035 (USD Billion)
Figure 10.8 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Figure 10.9 Antiviral Drugs Market for Human Immunodeficiency virus Infection, 2022-2035 (USD Billion)
Figure 10.10 Antiviral Drugs Market for Hepatitis Infection, 2022-2035 (USD Billion)
Figure 10.11 Antiviral Drugs Market for Herpes Simplex Virus Infection, 2022-2035 (USD Billion)
Figure 10.12 Antiviral Drugs Market for Cytomegalovirus Infection, 2022-2035 (USD Billion)
Figure 10.13 Antiviral Drugs Market for Influenza Infection, 2022-2035 (USD Billion)
Figure 10.14 Antiviral Drugs Market for Coronavirus Infection, 2022-2035 (USD Billion)
Figure 10.15 Antiviral Drugs Market for Other Target Indications, 2022-2035 (USD Billion)
Figure 10.16 Antiviral Drugs Market: Distribution by Drug Target, 2022 and 2035 (USD Billion)
Figure 10.17 Antiviral Drugs Market for Virus Targets, 2022-2035 (USD Billion)
Figure 10.18 Antiviral Drugs Market for Host Targets, 2022-2035 (USD Billion)
Figure 10.19 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Figure 10.20 Antiviral Drugs Market for Monotherapy, 2022-2035 (USD Billion)
Figure 10.21 Antiviral Drugs Market for Combination Therapy, 2022-2035 (USD Billion)
Figure 10.22 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Figure 10.23 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Figure 10.24 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Figure 10.25 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Figure 10.26 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Figure 10.27 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Figure 10.28 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

List Of Tables
Table 4.1 List of Approved Antiviral Drugs
Table 4.2 List of Approved Antiviral Drug Developers
Table 5.1 List of Clinical-Stage Antiviral Drugs
Table 5.2 List of Clinical-Stage Antiviral Drug Developers
Table 6.1 AbbVie: Product Portfolio
Table 6.2 AbbVie: Recent Developments and Future Outlook
Table 6.3 AstraZeneca: Product Portfolio
Table 6.4 AstraZeneca: Recent Developments and Future Outlook
Table 6.5 Bristol-Myers Squibb: Product Portfolio
Table 6.6 Bristol-Myers Squibb: Recent Developments and Future Outlook
Table 6.7 Genentech: Product Portfolio
Table 6.8 Genentech: Recent Developments and Future Outlook
Table 6.9 Gilead Sciences: Product Portfolio
Table 6.10 Gilead Sciences: Recent Developments and Future Outlook
Table 6.11 GlaxoSmithKline: Product Portfolio
Table 6.12 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.13 Johnson & Johnson: Product Portfolio
Table 6.14 Johnson & Johnson: Recent Developments and Future Outlook
Table 6.15 Merck: Product Portfolio
Table 6.16 Merck: Recent Developments and Future Outlook
Table 6.17 Novartis: Product Portfolio
Table 6.18 Novartis: Recent Developments and Future Outlook
Table 6.19 Pfizer: Product Portfolio
Table 6.20 Pfizer: Recent Developments and Future Outlook
Table 6.21 Roche: Product Portfolio
Table 6.22 Roche: Recent Developments and Future Outlook
Table 6.23 ViiV Healthcare: Product Portfolio
Table 6.24 ViiV Healthcare: Recent Developments and Future Outlook
Table 7.1 Antiviral Drugs: List of Partnerships and Collaborations
Table 8.1 Antiviral Drugs: List of Funding and Investments
Table 12.1 Approved Antiviral Drugs: Distribution by Year of Approval
Table 12.2 Approved Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.3 Approved Antiviral Drugs: Distribution by Type of Molecule
Table 12.4 Approved Antiviral Drugs: Distribution by Type of Target Virus
Table 12.5 Approved Antiviral Drugs: Distribution by Route of Administration
Table 12.6 Approved Antiviral Drugs: Distribution by Dosing Frequency
Table 12.7 Approved Antiviral Drugs: Distribution by Mechanism of Action
Table 12.8 Approved Antiviral Drugs: Distribution by Target Indication
Table 12.9 Approved Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.10 Approved Antiviral Drugs Developers: Distribution by Company Size
Table 12.11 Approved Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.12 Approved Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.13 Most Active Players: Distribution by Number of Approved Drugs
Table 12.14 Clinical Antiviral Drugs: Distribution by Phase of Development
Table 12.15 Clinical Antiviral Drugs: Distribution by Type of Molecule
Table 12.16 Clinical Antiviral Drugs: Distribution by Phase of Development and Type of Molecule
Table 12.17 Clinical Antiviral Drugs: Distribution by Type of Dosage Form
Table 12.18 Clinical Antiviral Drugs: Distribution by Route of Administration
Table 12.19 Clinical Antiviral Drugs: Distribution by Target Indication
Table 12.20 Clinical Antiviral Drugs: Distribution by Phase of Development and Target Indication
Table 12.21 Clinical Antiviral Drugs: Distribution by Type of Developer
Table 12.22 Clinical Antiviral Drugs: Distribution by Type of Therapy
Table 12.23 Clinical Antiviral Drugs: Distribution by Target Patient Segment (by Age)
Table 12.24 Clinical Antiviral Drugs: Distribution by Mechanism of Action
Table 12.25 Clinical Antiviral Drugs: Distribution by Type of Target Virus
Table 12.26 Clinical Antiviral Drugs: Distribution by Number of Doses
Table 12.27 Clinical Antiviral Drugs Developers: Distribution by Year of Establishment
Table 12.28 Clinical Antiviral Drugs Developers: Distribution by Company Size
Table 12.29 Clinical Antiviral Drugs Developers: Distribution by Geography (Region-wise)
Table 12.30 Clinical Antiviral Drugs Developers: Distribution by Geography (Country-wise)
Table 12.31 Clinical Antiviral Drugs Developers: Distribution by Company Size and Location of Headquarters
Table 12.32 Most Active Players: Distribution by Number of Clinical-Stage Drugs
Table 12.33 Partnerships and Collaborations: Distribution by Year of Partnership
Table 12.34 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.35 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.36 Partnerships and Collaborations: Distribution by Target Indication
Table 12.37 Partnerships and Collaborations: Distribution by Type of Target Virus
Table 12.38 Partnerships and Collaborations: Distribution by Type of Partner
Table 12.39 Most Active Players: Distribution by Number of Partnerships
Table 12.40 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 12.41 Partnerships and Collaborations: International and Local Deals
Table 12.42 Funding and Investments: Distribution by Year of Funding
Table 12.43 Funding and Investments: Distribution of Amount Invested by Year
Table 12.44 Funding and Investments: Distribution of by Type of Fundings
Table 12.45 Funding and Investments: Distribution of Amount Invested by Type of Funding
Table 12.46 Funding and Investments: Distribution by Target Indication
Table 12.47 Funding and Investments: Distribution by Type of Target Virus
Table 12.48 Funding and Investments: Distribution by Type of Investor
Table 12.49 Most Active Players: Distribution by Number of Instances
Table 12.50 Most Active Players: Distribution by Amount Invested
Table 12.51 Most Active Investors: Distribution by Number of Instances
Table 12.52 Funding and Investments: Distribution of Amount Invested by Region
Table 12.53 Funding and Investments: Distribution of Amount Invested by Country
Table 12.54 Global Antiviral Drugs Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.55 Antiviral Drugs Market: Distribution by Mechanism of Action, 2022 and 2035 (USD Billion)
Table 12.56 Antiviral Drugs Market for Fusion Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.57 Antiviral Drugs Market for DNA Polymerases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.58 Antiviral Drugs Market for Protease Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.59 Antiviral Drugs Market for Reverse Transcriptase Inhibitors, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.60 Antiviral Drugs Market for Other Mechanisms, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.61 Antiviral Drugs Market: Distribution by Target Indication, 2022 and 2035 (USD Billion)
Table 12.62 Antiviral Drugs Market for Human Immunodeficiency virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.63 Antiviral Drugs Market for Hepatitis Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.64 Antiviral Drugs Market for Herpes Simplex Virus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.65 Antiviral Drugs Market for Cytomegalovirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.66 Antiviral Drugs Market for Influenza Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.67 Antiviral Drugs Market for Coronavirus Infection, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.68 Antiviral Drugs Market for Other Target Indications, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.69 Antiviral Drugs Market: Distribution by Drug Target, 2022 and 2035 (USD Billion)
Table 12.70 Antiviral Drugs Market for Virus Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.71 Antiviral Drugs Market for Host Targets, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.72 Antiviral Drugs Market: Distribution by Type of Therapy, 2022 and 2035 (USD Billion)
Table 12.73 Antiviral Drugs Market for Monotherapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.74 Antiviral Drugs Market for Combination Therapy, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
Table 12.75 Antiviral Drugs Market: Distribution by Geography, 2022 and 2035 (USD Billion)
Table 12.76 Antiviral Drugs Market in North America, 2022-2035 (USD Billion)
Table 12.77 Antiviral Drugs Market in Europe, 2022-2035 (USD Billion)
Table 12.78 Antiviral Drugs Market in Asia-Pacific, 2022-2035 (USD Billion)
Table 12.79 Antiviral Drugs Market in Latin America, 2022-2035 (USD Billion)
Table 12.80 Antiviral Drugs Market in MENA, 2022-2035 (USD Billion)
Table 12.81 Antiviral Drugs Market in Rest of the World, 2022-2035 (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 101 Therapeutics
  • 30 TECHNOLOGY
  • 3M
  • 60 Degrees Pharmaceuticals (60P)
  • Aardvark Therapeutics
  • Aarhus University Hospital
  • AB Science
  • AbbVie
  • AbCellera
  • Abderrahmane Mami Hospital
  • Acerta Pharma
  • Acticor Biotech
  • Adage Capital Management
  • Adagio Therapeutics
  • Adamis Pharmaceuticals
  • Adimab
  • Adjuvant Capital
  • Advagene Biopharma
  • Aevi Genomic Medicine (acquired by Avalo Therapeutics)
  • Afyonkarahisar Health Sciences University
  • AGC Biologics
  • AgelessRx
  • AiPharma
  • Airway Therapeutics
  • Aisling Capital
  • Ajinomoto Bio-Pharma Services
  • Albatross Capital
  • Aldeyra Therapeutics
  • Alexandria Venture Investments
  • Algernon Pharmaceuticals
  • Aligos Therapeutics
  • AlloVir
  • Ally Bridge Group
  • Alnylam Pharmaceuticals
  • Alphamab
  • Altium Capital
  • Altum Pharmaceuticals (subsidiary of BetterLife's)
  • Amarex Clinical Research
  • American Gene Technologies International
  • amfAR
  • Amgen
  • Ampio Pharmaceuticals
  • Amplyx Pharmaceuticals
  • Amsterdam UMC
  • Amyndas Pharmaceuticals
  • Amzak Health
  • ANA Therapeutics (acquired by NeuroBo Pharmaceuticals)
  • Anaxago
  • Andera Partners
  • Angel Pharmaceuticals
  • ANRS
  • Ansun Biopharma
  • Antios Therapeutics
  • Antiva Biosciences
  • Anzu Partners
  • APCER Life Sciences
  • APEIRON Biologics
  • Apellis Pharmaceuticals
  • Apex Services
  • APICES
  • Appili Therapeutics
  • Applied Biology
  • AptaBio Therapeutics
  • Arbutus Biopharma
  • ARCA Biopharma
  • Ark Biosciences
  • Arrowhead Pharmaceuticals
  • ArrowMark Partners
  • ARTIS Ventures
  • Ascletis Pharma
  • Ashfield Engage
  • Ashvattha Therapeutics
  • Aspire Capital Fund
  • Assembly Biosciences
  • Assistance Publique - Hôpitaux de Paris
  • AstraZeneca
  • Atea Pharmaceuticals
  • Atreca
  • Atriva Therapeutics
  • aTyr Pharma
  • Austria Wirtschaftsservice Gesellschaft (aws)
  • Austrian Research Promotion Agency (FFG)
  • Avantor
  • Avego BioScience Capital (formerly known as Google Ventures)
  • Avestria Ventures
  • Avid Bioservices
  • Azidus Brasil
  • AzurRx BioPharma
  • Bain Capital Life Sciences
  • Banque Populaire
  • Bausch + Lomb
  • Bausch Health
  • Bayer
  • Baylor College of Medicine
  • BDgene
  • BDR Pharmaceuticals
  • Beech Tree Labs
  • BeiGene
  • Beijing Defengrei Biotechnology
  • Beijing Genova Biotech
  • Beijing Tiantan Biological Products
  • BerGenBio
  • Beximco Pharmaceuticals
  • Bharat Serums and Vaccines
  • Bill & Melinda Gates Foundation
  • Bill & Melinda Gates Medical Research Institute
  • BioAge Labs
  • BioAgilytix
  • BIOCAD
  • Bioclinica
  • Biocon Biologics
  • BioCryst Pharmaceuticals
  • Biogen
  • Biohaven Pharmaceuticals
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Bionorica
  • Biorasi
  • Biotest
  • Blade Therapeutics
  • BlueSky Immunotherapies
  • BNC Korea
  • BNK Venture Capital
  • Boan Biotech (a subsidiary of Luye Pharma Group)
  • Boehringer Ingelheim
  • Boxer Capital
  • Bpifrance
  • Brace Pharma Capital
  • Brigham and Women's Hospital
  • Brii Biosciences
  • Bristol-Myers Squibb
  • BronxCare Health System
  • Bukwang Pharmaceutical
  • Cadila Healthcare
  • California Institute for Regenerative Medicine (CIRM)
  • CAM Capital
  • Cambridge Innovation Capital
  • Canaan Partners
  • Cancer Research Institute
  • Can-Fite BioPharma
  • Cardresearch
  • Carelink Pharmaceutical
  • Cascade Chemistry
  • Celgene
  • Celltrion
  • Celonic
  • Celularity
  • Cenduit
  • Cenexi
  • Center for Drug Evaluation (CDE), Taiwan
  • Chemical Diversity Research Institute
  • Chime Biologics
  • China Immunotech (Beijing) Biotechnology
  • China Meheco
  • China National Biotec Group
  • China Venture Capital Fund
  • Chinese Academy of Medical Sciences
  • Chong Kun Dang Pharmaceutical
  • CHRISTUS Health
  • Chromis
  • CICC Qide
  • Cipla
  • Clear Creek Bio
  • Clearpool https://www.zoominfo.com/c/clinedem/532452984
  • Clene Nanomedicine
  • Clinedem
  • CLINICAL RESEARCH VIET NAM SKILL TRAINING AND CONSULTING
  • Clinical Service Center
  • Clinical Trial Consultants
  • Clinigen
  • Clinipace
  • Cocrystal Pharma
  • Code Pharma
  • Colorado Prevention Center
  • Columbia University
  • Copycat Sciences
  • CORAT Therapeutics
  • Cormorant Asset Management
  • Coronavirus Immunotherapy Consortium (CoVIC)
  • Corpometria Institute
  • Corvus Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Cota Capital
  • CR Double-Crane
  • CR-CP Life Science Fund
  • Cromos Pharma
  • CSL Behring
  • CTI Clinical Trial and Consulting Services
  • Cue Biopharma
  • Curavit Clinical Research
  • CytoDyn
  • Daewoong Pharmaceuticals
  • DalCor Pharmaceuticals
  • DataMap
  • Datametrix
  • DCVC Bio
  • Debiopharm
  • Defense Advanced Research Projects Agency (DARPA)
  • Defense Health Agency (DHA)
  • Definvest
  • Delos Capital
  • Department of Health and Human Services
  • Dermapharm
  • Dicerna Pharmaceuticals
  • dievini Hopp Biotech
  • Diffusion Pharmaceuticals
  • Domain Associates
  • Dompé
  • Dong-A ST
  • Dongguan HEC TaiGen Biopharmaceuticals
  • Door Pharmaceuticals
  • Dr. Reddy’s Laboratories
  • DSG
  • Duke-NUS Medical School
  • ECOGENE-21
  • Edesa Biotech
  • eFFECTOR Therapeutics
  • EIC Fund
  • Eiger BioPharmaceuticals
  • Elaia
  • Eli Lilly
  • ELPEN
  • EMD Serono
  • Emergent BioSolutions
  • Emergo Therapeutics
  • Emory University
  • EmphyCorp
  • Enanta Pharmaceuticals
  • ENYO Pharma
  • EOM Pharmaceuticals
  • Epiq Capital
  • EQRx
  • Equilab International
  • Erasmus University Medical Center
  • Erste Bank
  • Eshmoun-Clinical Research
  • Etana Biotechnologies
  • Eunice Kennedy Shriver National Institute of Child Health and Human
  • European Commission
  • European Investment Bank
  • European Union
  • Everest Medicines
  • Everest Venture Capital
  • Evergreen Therapeutics
  • Evive Biotech
  • Excision BioTherapeutics
  • Exvastat
  • Eye & ENT Hospital of Fudan University
  • Fab'entech
  • Family First Medical Research Center
  • Farmak
  • Farmoquímica
  • Federal Budget Institution of Science
  • Central Research Institute of Epidemiology of Rospotrebnadzor
  • Federal Government of Switzerland
  • Federated Hermes
  • FengChuan capital
  • FHI Clinical
  • Fidelity Management & Research
  • First Light Asset Management
  • First Wave BioPharma
  • Flanders Innovation & Entrepreneurship
  • Florence Healthcare
  • Foresite Capital
  • Forest Pharmaceuticals
  • Fosun Pharma
  • Founders Fund
  • Fraunhofer Institute for Molecular Biology and Applied Ecology
  • Community Regional Medical Center
  • Frontier Biotechnologies
  • Fujian Cosunter Pharmaceutical
  • FUJIFILM Diosynth Biotechnologies
  • FUJIFILM Pharmaceuticals
  • FUJIFILM Toyama Chemical
  • Gaingels
  • Genentech
  • Generation Bio
  • Genexine
  • Genoscience Pharma
  • George Clinical
  • German Federal Ministry of Education and Research
  • Federal Ministry of Health (Germany)
  • Ghent University Hospital
  • Ghost Tree Capital
  • GIC
  • Gilead Sciences
  • Global Response Aid (GRA)
  • Golden Biotechnology
  • GordonMD Global Investments
  • Gorgas Memorial Institute for Health Studies (GMI)
  • Government of Canada
  • Government of France
  • Grand Medical
  • Granite Point Capital Management
  • GreatPoint Ventures
  • Green Sands Equity
  • Grifols Therapeutics
  • GSK
  • Guangzhou Henovcom Bioscience
  • Guangzhou Lupeng Pharmaceutical
  • GV
  • Halozyme Therapeutics
  • Hamad Medical
  • Hankang Capital
  • Harbour BioMed
  • HBM Healthcare Investments
  • HealthCor Management
  • Heartland Healthcare Capital
  • Hebei Yanda Ludaopei Hospital
  • Heidelberg ImmunoTherapeutics
  • Heilongjiang ZBD Pharmaceutical
  • HeNan Sincere Biotech
  • Hengenix Biotech
  • Hengxu Capital
  • Hepion Pharmaceuticals
  • HiFiBiO Therapeutics
  • High-Tech Gründerfonds (HTGF)
  • Hinova Pharmaceuticals
  • HitGen
  • Hongtao Capital
  • HOOKIPA Pharma
  • Hospital Alemão Oswaldo Cruz
  • Hospital Casa de Saúde
  • Hospital do Coração
  • Hospital Israelita Albert Einstein
  • Hospital Moinhos de Vento
  • Hospital Santo Tomás
  • Huadong Medicine
  • Huahui Health
  • Humanigen
  • Huoshenshan Hospital
  • hVIVO
  • ICLPharma
  • ICON
  • IGM Biosciences
  • ILTOO Pharma
  • I-Mab Biopharma
  • Immune Biosolutions
  • Immune System Regulation (ISR)
  • Immunic
  • ImmunityBio
  • ImmunoCellular Therapeutics
  • Imuneks Farma
  • Incepta Pharmaceuticals
  • Incozen
  • Incyte
  • IndusAge Partners
  • Infectious Disease Research Institute (IDRI)
  • InnoStar Solutions
  • Innovation Pharmaceuticals
  • Innovent Biologics
  • Inotrem
  • Inova Health System
  • Instat Clinical Research
  • Institut Mérieux
  • Institut Pasteur Korea
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network
  • InterX
  • Invesco Developing Markets Fund
  • Invus
  • Ionis Pharmaceuticals
  • IQVIA
  • Israeli Ministry of Health (MoH)
  • J.P. Morgan Securities
  • Janssen
  • Janus Henderson Investors
  • Japan Agency for Medical Research and Development
  • Jazz Pharmaceuticals
  • Jena University Hospital
  • Jiangsu Famaison Medical Technology
  • Jiangsu Hansoh Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Jiangsu Pacific Meinuoke Bio-pharmaceutical
  • Johns Hopkins University
  • Johnson & Johnson
  • JSS Medical Research
  • Junshi Biosciences
  • JX Partners
  • KABS Laboratories
  • Kamada
  • Kansas State University
  • Karyopharm Therapeutics
  • Kedrion Biopharma
  • KGbio
  • Kinevant Sciences
  • King Pharmaceuticals
  • Kiniksa Pharmaceuticals
  • Kintor Pharmaceutical
  • Kite Pharma
  • Korea Institute of Radiological & Medical Sciences
  • Korea United Pharm
  • Kowa
  • KPM Tech
  • Kreaxi
  • KResearch
  • KU Leuven
  • Kukbo
  • Kyorin Pharmaceutical
  • Kyowa Kirin
  • Kyushu University
  • LabCorp Drug Development
  • Labo'Life
  • Laboratoire Boréaderme
  • Laboratorios Silanes
  • Lake Bleu Capital
  • Laurent Pharma
  • Leidos
  • Lewis Katz School of Medicine
  • LFB
  • LianBio
  • LifeSci Venture Partners
  • Ligand Pharmaceuticals
  • Light Chain Bioscience
  • Lilly Asia Ventures (LAV)
  • Lind Global Fund II
  • Linear Clinical Research
  • List Biological Laboratories
  • Logos Capital
  • Loreda Holdings
  • Lumira Ventures
  • Lung Biotechnology
  • Lupin
  • Luxna Biotech
  • Luye Pharma
  • M.D. Anderson Cancer Center
  • M28 Capital
  • mAbxience
  • MacroGenics
  • Shenzhen Maiwei BioTech
  • Malakoff Humanis
  • Mana Ventures
  • Massachusetts General Hospital
  • Matrix Partners China
  • Mayo Clinic
  • Athens Medical Society
  • Medical University of Silesia
  • Medical University of Vienna
  • MediciNova
  • MedImmune
  • Medpace
  • MedRegen
  • Memorial Sloan Kettering Cancer Center
  • Meneldor
  • Merck
  • Merck KGaA
  • Merck Sharp & Dohme
  • Mereo BioPharma
  • MetrioPharm
  • Metro International Biotech
  • Ministry of Health (Morocco)
  • MiNK Therapeutics
  • Missouri State University
  • Mithril
  • ModeX Therapeutics
  • Molecular Partners
  • Institut de recherches cliniques de Montréal (IRCM)
  • Moorim Capital
  • Morningside Ventures
  • Mount Sinai Health System
  • Mylan
  • Nabuboto
  • Nanjing Sanhome Pharmaceutical
  • NantKwest
  • National Cancer Institute (NCI)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Center for Global Health and Medicine
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Mental Health (NIMH)
  • National Institute on Deafness and Other Communication Disorders (NIDCD)
  • National Institutes of Health (NIH)
  • National Research Council of Canada Industrial Research Assistance Program
  • National University Hospital, Singapore
  • National University of Singapore
  • Natural Capital Investment Fund
  • Naval Medical Research Unit 3 (NAMRU-3)
  • Navigen
  • NBank Capital
  • NEAT ID Foundation
  • Nektar Therapeutics
  • NeoImmuneTech
  • Neurelis
  • NeuroActiva
  • NeuroBo Pharmaceuticals
  • NeuroRx
  • NeuTec Pharma (acquired by Novartis)
  • Neutrolis
  • New Leaf Venture Partners
  • Newsoara BioPharma
  • NiKang Therapeutics
  • Nobelpharma
  • Noblewell
  • Noorik Biopharmaceuticals
  • Norwest Venture Partners
  • Norwich Clinical Research Associates
  • Nova Healthcare
  • Novartis
  • Novatek Pharmaceuticals
  • Novo Holdings
  • Nucorion Pharmaceuticals
  • OBCTCD24
  • Ohara Pharmaceutical
  • Oklahoma State University
  • Olatec Therapeutics
  • Olive Tree Capital
  • Omega Funds
  • OncoImmune (acquired by Merck)
  • Opera
  • Ophirex
  • OPKO Health
  • OrbiMed
  • OrbiMed Advisors
  • Organicell Regenerative Medicine
  • Osage University Partners
  • Paidion Research (acquired by Premier Research)
  • Palo Alto Pharmaceuticals
  • Pardes Biosciences
  • Partner Therapeutics
  • PDS Biotechnology
  • Peking University First Hospital
  • Perceptive Advisors
  • Petrovax
  • Pfizer
  • Pharco Pharmaceuticals
  • Pharma Holdings
  • Pharma Nord
  • Pharmaceutical Solutions
  • PharmaEssentia
  • PharmaMar
  • Pharmascience
  • PHARMENTERPRISES
  • Pharm-Olam
  • Pharmsynthez
  • Pivotal bioVenture Partners
  • Plum Alley Investments
  • Polaris Partners
  • Polish Medical Research Agency (ABM)
  • Pontifax
  • Pontificia Universidad Católica de Chile
  • Population Health Partners
  • Population Health Research Institute (PHRI)
  • POSCO Capital
  • PPD
  • Premji Invest
  • Presight Capital
  • PRISM BioLab
  • Proteros Biostructures
  • Prothione
  • Proxima Clinical Research
  • PT Lloyd Pharma
  • PTC Therapeutics
  • Pulmoquine Therapeutics
  • Pulmotect
  • Pulthera
  • PureTech Health
  • Q2 Solutions
  • QbD Clinical
  • Qilu Pharmaceutical
  • Jiangxi Qingfeng Pharmaceutical
  • Quercis Pharma
  • R&G PharmaStudies
  • RA Capital Management
  • Rabin Medical Center
  • Radboud University Medical Center
  • Rawalpindi Medical University
  • Guangdong Raynovent Biotech
  • RedHill Biopharma
  • Redmile Group
  • Regeneron Pharmaceuticals
  • Resolve Therapeutics
  • Resverlogix
  • Retrograde Investments
  • RetroLead (Shanghai) BioPharma
  • Reven Pharmaceuticals
  • RevImmune
  • ReViral (acquired by Pfizer)
  • Revive Therapeutics
  • Rhizen Pharmaceuticals
  • Ride Wave Ventures
  • Ridgeback Biotherapeutics
  • Rigel Pharmaceuticals
  • Roche
  • Rock Springs Capital
  • Rockefeller University
  • Laboratorios Roemmers
  • Roivant Sciences
  • Romark
  • R-Pharm
  • RQ Biotechnology
  • Ruijin Hospital
  • Russian Academy of Medical Sciences
  • SAB Biotherapeutics
  • Sagent Pharmaceuticals
  • Saigon Biopharma
  • Saint Luke’s Mid America Heart Institute
  • Samel
  • Samsara BioCapital
  • Samsung BioLogics
  • Sanofi
  • Sao Thai Duong Joint Stock Company
  • SCiAN Services
  • Scientific Center for Anti-infectious Drugs
  • Sciwind Biosciences
  • Scotmann Pharmaceuticals
  • Scripps Research
  • Sectoral Asset Management
  • Selva Therapeutics
  • Senhwa Biosciences
  • Seoul Investment Partners
  • SGS
  • Shanghai East Hospital
  • Shanghai Free Trade Zone Equity Investment Fund
  • Shanghai Hepu Pharmaceutical
  • Shanghai Pharmaceuticals
  • Shanghai Tongren Hospital
  • Shanxi Kangbao Biological Product
  • Shaperon
  • Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (IBCh)
  • Shenyang Tonglian Pharmaceutical
  • Shenzhen Co-way Capital Services
  • Shenzhen Share Capital
  • Shin Poong Pharma
  • Shionogi
  • SIGA Technologies
  • Sigma Gestion
  • SigmaDrugs
  • Simbec-Orion
  • Singapore Clinical Research Institute (SCRI)
  • Singlomics Biopharmaceuticals
  • Sinopharm
  • Sinopharm-CICC Capital
  • Sirona Capital
  • Sironax
  • Sixty Degree Capital
  • SmartPharm Therapeutics
  • Smilegate Investment
  • SOCAR Research
  • Societe Generale
  • Sofinnova Ventures
  • Soleus Capital
  • SomaLogic
  • Soroka Medical Center
  • Sorrento Therapeutics
  • Sound Pharmaceuticals
  • South Dakota Equity Partners
  • Staidson Biopharma
  • Statera Biopharma
  • Stemedica Cell Technologies
  • Sun Pharma
  • Sunshine Lake Pharma (a subsidiary of HEC Pharm)
  • SuperGene
  • Supriya LifeScience
  • Surveyor Capital
  • Swiss National Science Foundation (SNSF)
  • Synairgen
  • Syneos Health
  • TaiGen Biotechnology
  • TaiMed Biologics
  • TaiwanJ Pharmaceuticals
  • Takeda Pharmaceuticals
  • Telcon RF Pharmaceutical
  • Telios Pharma
  • Temasek
  • The Medicines Patent Pool (MPP)
  • The Montreal Health Innovations Coordinating Center (MHICC)
  • The Supreme Council for the Arab-African Economy
  • The Vienna Business Agency
  • Theravance Biopharma
  • Thermo Fisher Scientific
  • Third People's Hospital of Shenzhen
  • Thrombosis Research Institute
  • Tiantu Capital
  • TLC BioSciences
  • Tokyo Metropolitan Komagome Hospital
  • Tokyo Shinagawa Hospital
  • Toscana Life Sciences
  • Transcenta
  • Tribe Capital
  • Trinity Health
  • TSB Therapeutics
  • Tsinghua University
  • Turn Therapeutics
  • Turnstone Biologics
  • Tychan
  • U.S. Department of Defense
  • U.S. Department of Health and Human Services (HHS)
  • UCB Pharma
  • United BioPharma
  • United Medical Specialties
  • United Nations Children’s Fund (UNICEF)
  • United States Department of Defense
  • UnitedHealth Group
  • University Hospital, Basel, Switzerland
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec
  • University Medical Center Goettingen
  • University Medical Center of Johannes Gutenberg University Mainz
  • University of Aarhus
  • University of Alabama at Birmingham
  • University of Arizona
  • University of California
  • University of Chicago
  • University of Cologne
  • University of Michigan
  • University of Minnesota
  • University of Nairobi
  • University of Nebraska
  • University of Oxford
  • University of Pennsylvania
  • University of Utah
  • US Biotest
  • US Government
  • Utrecht University
  • Valeant Pharmaceuticals (now Bausch Health)
  • Valenta Pharm
  • Valiant Capital Partners
  • Vanderbilt University Medical Center
  • Vasomune Therapeutics
  • VBL Therapeutics
  • Venrock Healthcare Capital Partners
  • Veranex
  • Verastem Oncology
  • Verrica Pharmaceuticals
  • Veru
  • VetStem Biopharma
  • Via Christi Research
  • Vienna Insurance Group (VIG)
  • Vietstar Biomedical Research
  • Vigonvita Life Sciences
  • ViiV Healthcare
  • Viking Global Investors
  • Vir Biotechnology
  • ViralClear
  • Viriom
  • VirTrial
  • Visterra
  • Hainan Visum Pharmaceutical (acquired by TWi Pharmaceuticals)
  • Wellington Management Company
  • Westat
  • Windtree Therapeutics
  • WRVI Capital
  • X-Chem
  • XENOTHERA
  • Xi'an Xintong Pharmaceutical Research
  • Yuanta Investment
  • Zhejiang Hisun Pharmaceutical

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Antiviral Combination Therapy Global Market Report 2024 - Product Image

Antiviral Combination Therapy Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Antiviral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Drug Pipelines
  • 150 Pages
  • Global
From
Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030 - Product Image

Antiviral Therapeutics Market by Drug, Therapy, Distribution - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Antiviral Combination Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Antiviral Combination Therapy Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Global Forecast 2025-2030 - Product Image

Direct-acting Antiviral Drug Market by Type, Indication, Route, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.